Considering taking a position in PAA. It seems all 12 patients in the Phase 1 study have now survived well past the average period under the gold standard for the currently approved treatment plus with minimal side effects. All patients also wish to continue treatment. So seeing great efficacy in a safety study. In simple terms, what is the downside here at the moment?
Ann: FDA Grants PharmAust Pre-IND Meeting, page-31
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.005(2.22%) |
Mkt cap ! $97.90M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.0¢ | $89.21K | 403.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 144172 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 144585 | 4 |
View Market Depth
| Last trade - 15.31pm 17/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |